Shares of Sequenom rose 11 percent for the four-day trading period ended Tuesday. Almost all of that increase came after Oppenheimer analyst Sean Lavin on Monday initiated the stock with a “buy” rating. Lavin put an $8 price target on Sequenom’s shares, which were trading at $5.20 on Wednesday afternoon.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.